oral semaglutide clinical trials Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes FDA Approves First ORAL GLP-1

Recent clinical data shows that GLP-1 receptor agonists like semaglutide can reduce cholesterol levels while promoting weight loss, offering a two-pronged approach to cardiovascular health

Wang YK, Ran DM, Li YY, Zhu CY, Zhang RB, Jiang B, et al

Approval of tirzepatide for apnea was given on the basis of a study that showed the drug reduced the condition by up to 62.8 percent

An additional study compared weight loss outcomes for semaglutide and tirzepatide but used data specifically for these medications labeled for T2DM and thus included a large (52%) proportion of patients with T2DM

Companies such as Ro, WeightWatchers, and Noom offer users a convenient and perhaps less intimidating platform for accessing the weight-loss drugs